Medicare Part D drugs starting with L
115 drugs start with L; 61 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for lenalidomide in 2024: $2.6 billion, what plans and patients paid at the pharmacy before rebates.
Which drugs start with L?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Labetalol hydrochloride | 100% | Tier 2 | $30 million |
| Lacosamide | 100% | Tier 4 | $111 million |
| Lactulose | 100% | Tier 2 | $60 million |
| Lagevrio (molnupiravir) | 26.7% | Tier 3 | $121 million |
| Lamictal (lamotrigine) | 1.7% | Tier 4 | $111 million |
| Lamivudine | 100% | Tier 3 | $3 million |
| Lamivudine / zidovudine | 100% | Tier 4 | $2 million |
| Lamotrigine | 100% | Tier 1 | $109 million |
| Lampit (nifurtimox) | 22.5% | Tier 4 | no 2024 match |
| Lanoxin (digoxin) | 1.9% | Tier 4 | $967 thousand |
| Lansoprazole | 93.5% | Tier 2 | $47 million |
| Lanthanum carbonate | 4.9% | Tier 2 | $44 million |
| Lantus (insulin glargine) | 96.9% | Tier 3 | $839 million |
| Lapatinib | 100% | Tier 5 | $6 million |
| Larin (ethinyl estradiol / norethindrone acetate) | 95% | Tier 2 | $99 thousand |
| Larin Fe (ethinyl estradiol / norethindrone acetate) | 95.3% | Tier 2 | $133 thousand |
| Latanoprost | 100% | Tier 1 | $130 million |
| Latuda (lurasidone hydrochloride) | 0.3% | Tier 5 | $40 million |
| Lazcluze (lazertinib) | 100% | Tier 5 | $7 million |
| Ledipasvir / sofosbuvir | 16.9% | Tier 5 | $3 million |
| Leflunomide | 100% | Tier 2 | $35 million |
| Lenalidomide | 100% | Tier 5 | $2.6 billion |
| Lenvima (lenvatinib) | 100% | Tier 5 | $876 million |
| Leqembi (lecanemab-irmb) | 1.3% | Tier 5 | $514 thousand |
| Leqselvi (deuruxolitinib) | 3% | Tier 5 | no 2024 match |
| Lessina (ethinyl estradiol / levonorgestrel) | 94.2% | Tier 2 | $49 thousand |
| Letairis (ambrisentan) | 0.2% | Tier 5 | $83 million |
| Letrozole | 100% | Tier 2 | $19 million |
| Leucovorin | 100% | Tier 2 | $5 million |
| Leukeran (chlorambucil) | 100% | Tier 5 | $17 million |
| Leukine (sargramostim) | 9.3% | Tier 5 | $3 million |
| Leuprolide acetate | 98.5% | Tier 4 | $14 thousand |
| Levalbuterol | 84.8% | Tier 3 | $2 million |
| Levetiracetam | 100% | Tier 2 | $157 million |
| Levobunolol hydrochloride | 100% | Tier 2 | $1 million |
| Levocarnitine | 95.4% | Tier 4 | $6 million |
| Levocetirizine dihydrochloride | 100% | Tier 1 | $28 million |
| Levofloxacin | 100% | Tier 1 | $15 million |
| Levonest (ethinyl estradiol / levonorgestrel) | 95% | Tier 2 | $11 thousand |
| Levorphanol tartrate | 2.5% | Tier 1 | $14 million |
Show the other 75 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Levothyroxine sodium | 100% | Tier 1 | $464 million |
| Levoxyl (levothyroxine sodium) | 93.3% | Tier 1 | $6 million |
| Lexapro (escitalopram) | under 0.1% | Tier 1 | $18 million |
| Lialda (mesalamine) | under 0.1% | Tier 1 | $7 million |
| Lidocaine | 100% | Tier 4 | $160 million |
| Lidocaine / prilocaine | 99.8% | Tier 2 | $8 million |
| Lidocaine hydrochloride | 100% | Tier 2 | $2 million |
| Lidocan (lidocaine) | 47.9% | Tier 4 | $173 thousand |
| Liletta (levonorgestrel) | 73.6% | Tier 3 | $30 thousand |
| Linezolid | 100% | Tier 4 | $18 million |
| Linzess (linaclotide) | 100% | Tier 3 | $2.0 billion |
| Liomny (liothyronine sodium) | 94% | Tier 2 | no 2024 match |
| Liothyronine sodium | 99.7% | Tier 2 | $29 million |
| Lipitor (atorvastatin) | under 0.1% | Tier 1 | $27 million |
| Lipofen (fenofibrate) | 0.2% | Tier 4 | $168 thousand |
| Liraglutide | 14% | Tier 2 | $48 million |
| Lisdexamfetamine dimesylate | 50.4% | Tier 4 | $44 million |
| Lisinopril | 100% | Tier 1 | $253 million |
| Litfulo (ritlecitinib) | 5.5% | Tier 5 | $5 million |
| Lithium carbonate | 100% | Tier 1 | $14 million |
| Lithium citrate | 99.7% | Tier 2 | $139 thousand |
| Lithobid (lithium carbonate) | under 0.1% | Tier 1 | $1 million |
| Lithostat (acetohydroxamic acid) | 4.9% | Tier 4 | $651 thousand |
| Livalo (pitavastatin calcium) | 16.5% | Tier 3 | $91 million |
| Livdelzi (seladelpar) | 4.9% | Tier 5 | $14 million |
| Livmarli (maralixibat) | 5.4% | Tier 5 | $8 million |
| Livtencity (maribavir) | 100% | Tier 5 | $52 million |
| Lo Loestrin Fe (ethinyl estradiol / norethindrone acetate) | 0.9% | Tier 4 | $1 million |
| Lodine (etodolac) | 1.5% | Tier 2 | no 2024 match |
| Lodoco (colchicine) | 0.4% | Tier 4 | $606 thousand |
| Loestrin (ethinyl estradiol / norethindrone acetate) | 55.3% | Tier 2 | $12 thousand |
| Loestrin Fe (ethinyl estradiol / norethindrone acetate) | 55.3% | Tier 2 | $16 thousand |
| Lofexidine | 6% | Tier 5 | $421 thousand |
| Lojaimiess (ethinyl estradiol) | 65.9% | Tier 2 | $25 thousand |
| Lokelma (sodium zirconium cyclosilicate) | 97% | Tier 3 | $239 million |
| Lomotil (atropine sulfate / diphenoxylate hydrochloride) | 0.1% | Tier 4 | $247 thousand |
| Lomustine | 99.8% | Tier 4 | no 2024 match |
| Lonsurf (tipiracil / trifluridine) | 100% | Tier 5 | $226 million |
| Loperamide hydrochloride | 97.7% | Tier 2 | $17 million |
| Lopinavir / ritonavir | 100% | Tier 4 | $3 million |
| Lopressor (metoprolol tartrate) | under 0.1% | Tier 1 | $310 thousand |
| Lorazepam | 100% | Tier 2 | $52 million |
| Lorbrena (lorlatinib) | 100% | Tier 5 | $117 million |
| Loryna (drospirenone / ethinyl estradiol) | 92.1% | Tier 2 | $176 thousand |
| Losartan potassium | 100% | Tier 1 | $355 million |
| Lotemax (loteprednol etabonate) | 71.1% | Tier 3 | $10 million |
| Lotensin (benazepril hydrochloride) | under 0.1% | Tier 1 | no 2024 match |
| Loteprednol etabonate | 70.9% | Tier 2 | $34 million |
| Loteprednol etabonate / tobramycin | 34.2% | Tier 3 | no 2024 match |
| Lovastatin | 100% | Tier 1 | $25 million |
| Lovaza (omega-3 acid ethyl esters) | under 0.1% | Tier 1 | $7 million |
| Lovenox (enoxaparin sodium) | under 0.1% | Tier 1 | $577 thousand |
| Low-Ogestrel (ethinyl estradiol / norgestrel) | 95.2% | Tier 2 | $114 thousand |
| Loxapine | 100% | Tier 2 | $4 million |
| Lubiprostone | 86.6% | Tier 3 | $56 million |
| Luizza (ethinyl estradiol / norethindrone acetate) | 86% | Tier 2 | no 2024 match |
| Lumakras (sotorasib) | 100% | Tier 5 | $154 million |
| Lumigan (bimatoprost) | 95.2% | Tier 3 | $647 million |
| Lumryz (sodium oxybate) | 20.2% | Tier 5 | $16 million |
| Lupkynis (voclosporin) | 1.2% | Tier 5 | $26 million |
| Lupron (leuprolide acetate) | 100% | Tier 5 | $165 million |
| Lurasidone hydrochloride | 100% | Tier 4 | $183 million |
| Lurbiro (flurbiprofen) | 2.4% | Tier 2 | no 2024 match |
| Lutera (ethinyl estradiol / levonorgestrel) | 87.2% | Tier 2 | $43 thousand |
| Lutrate (leuprolide acetate) | 25.2% | Tier 4 | no 2024 match |
| Lybalvi (olanzapine / samidorphan) | 48.1% | Tier 5 | $127 million |
| Lyleq (norethindrone) | 92.2% | Tier 2 | $572 |
| Lyllana (estradiol) | 64.1% | Tier 3 | $3 million |
| Lynkuet (elinzanetant) | 0.3% | Tier 4 | no 2024 match |
| Lynparza (olaparib) | 100% | Tier 5 | $594 million |
| Lyrica (pregabalin) | under 0.1% | Tier 1 | $62 million |
| Lysodren (mitotane) | 100% | Tier 5 | $3 million |
| Lytgobi (futibatinib) | 100% | Tier 5 | $22 million |
| Lyumjev (insulin lispro-aabc) | 31.4% | Tier 3 | $90 million |
| Lyza (norethindrone) | 96.5% | Tier 2 | no 2024 match |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans